Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
CytoDyn Inc. (CYDY)
USD0.21
-0.01 (-3.18%)
US OTC Healthcare Biotechnology
Address
1111 Main Street 98660
Vancouver, WA, US
Vancouver, WA, US
CEO
Jacob Lalezari
Website
cytodyn.com
IPO
2006-12-13
CIK 1175680 ISIN US23283M1018
Description
CytoDyn Inc. functions as a biotechnology enterprise currently in its clinical development phase. The company primarily concentrates on crafting therapies for a variety of medical conditions, leveraging leronlimab – an innovative humanized monoclonal antibody designed to interact with the CCR5 receptor. This experimental drug is being explored for its potential applications in human immunodeficiency virus (HIV), non-alcoholic steatohepatitis (NASH), various oncological diseases, and coronavirus disease (COVID-19). In addition, leronlimab is undergoing a Phase 1b/2 clinical investigation specifically for metastatic triple-negative breast cancer. Established in 2002, and previously operating as RexRay Corporation, CytoDyn Inc. is headquartered in Vancouver, Washington.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD0.21
-0.01 (-3.18%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
2M
Beta
1.12
Float Shares
1.37B
Free Float %
100.0%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -3.03% | +1.59% | +8.88% | +30.72% | +32.49% | +14.29% | -16.23% | +23.55% | -86.99% | -68.00% | -50.77% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (2 ratings, all time)
Buy
Price Targets & DCF
Current price
0.21
Ratings Trend (MoM)
100% Bullish
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | -1 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
-76.73
Distress
Piotroski F-Score
2 / 9
Weak
MOAT Score
1 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
5 / 5
High
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%+103.4% ★ Q1'26: +4.8% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%+209.8%
-
EBIT margin Biotechnology: +0.0%-145.4%
-
ROIC Biotechnology: -16.1%— Q1'26: +17.6% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+28.2% Q1'26: +3.8% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×3.17× Q1'26: -1.08× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
May 2025 actual |
May 2026 1 EPS Ana. |
May 2027 1 EPS Ana. |
May 2028 1 EPS Ana. |
May 2029 1 EPS Ana. |
May 2030 1 EPS Ana. |
May 2031 1 EPS Ana. |
May 2032 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|
| Revenue |
-5.92M
est: -5.92M (+0.0%)
|
-4.44M
-4.44M – -4.44M
+25.0% YoY
|
-3.33M
-3.33M – -3.33M
+25.0% YoY
|
-2.50M
-2.50M – -2.50M
+25.0% YoY
|
-1.87M
-1.87M – -1.87M
+25.0% YoY
|
-1.40M
-1.40M – -1.40M
+25.0% YoY
|
-1.05M
-1.05M – -1.05M
+25.0% YoY
|
-789.7K
-789.7K – -789.7K
+25.0% YoY
|
| EBITDA |
8.62M
est: -1.18M (+828.4%)
|
-887.4K
-887.4K – -887.4K
+25.0% YoY
|
-665.5K
-665.5K – -665.5K
+25.0% YoY
|
-499.2K
-499.2K – -499.2K
+25.0% YoY
|
-374.4K
-374.4K – -374.4K
+25.0% YoY
|
-280.8K
-280.8K – -280.8K
+25.0% YoY
|
-210.6K
-210.6K – -210.6K
+25.0% YoY
|
-157.9K
-157.9K – -157.9K
+25.0% YoY
|
| EBIT |
8.60M
est: -1.18M (+826.9%)
|
-887.4K
-887.4K – -887.4K
+25.0% YoY
|
-665.5K
-665.5K – -665.5K
+25.0% YoY
|
-499.2K
-499.2K – -499.2K
+25.0% YoY
|
-374.4K
-374.4K – -374.4K
+25.0% YoY
|
-280.8K
-280.8K – -280.8K
+25.0% YoY
|
-210.6K
-210.6K – -210.6K
+25.0% YoY
|
-157.9K
-157.9K – -157.9K
+25.0% YoY
|
| Net Income |
3.75M
est: -298.30M (+101.3%)
|
-242.37M
-242.37M – -242.37M
+18.8% YoY
|
-385.31M
-385.31M – -385.31M
-59.0% YoY
|
-248.58M
-248.58M – -248.58M
+35.5% YoY
|
-273.44M
-273.44M – -273.44M
-10.0% YoY
|
-261.01M
-261.01M – -261.01M
+4.5% YoY
|
-223.73M
-223.73M – -223.73M
+14.3% YoY
|
-223.73M
-223.73M – -223.73M
+0.0% YoY
|
| SGA |
7.26M
est: -199.16M (+103.6%)
|
-149.37M
-149.37M – -149.37M
+25.0% YoY
|
-112.03M
-112.03M – -112.03M
+25.0% YoY
|
-84.02M
-84.02M – -84.02M
+25.0% YoY
|
-63.02M
-63.02M – -63.02M
+25.0% YoY
|
-47.26M
-47.26M – -47.26M
+25.0% YoY
|
-35.45M
-35.45M – -35.45M
+25.0% YoY
|
-26.58M
-26.58M – -26.58M
+25.0% YoY
|
| EPS |
0.00
est: -0.24 (+100.8%)
|
-0.20
-0.20 – -0.20
+18.8% YoY
|
-0.31
-0.31 – -0.31
-59.0% YoY
|
-0.20
-0.20 – -0.20
+35.5% YoY
|
-0.22
-0.22 – -0.22
-10.0% YoY
|
-0.21
-0.21 – -0.21
+4.5% YoY
|
-0.18
-0.18 – -0.18
+14.3% YoY
|
-0.18
-0.18 – -0.18
+0.0% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-01 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-22.94M
OE per share TTM
-0.02
Owner's Yield
-5.62%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
-42.1%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
4
Total invested
64.1K
Insider transactions (90d)
0
Beneficial owners (>5%)
29
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | David F. Welch | 50.92M | 5.50% | 50.92M | — | 50.92M | — | IN | — | 2023-10-25 | ↗ |
| 2 | Dr. Richard G. Pestell | 11.44M | 1.87% | 8.34M | 3.09M | 8.34M | 3.09M | IN | — | 2021-06-08 | ↗ |
| 3 | Dr. Richard Pestell | 11.44M | 1.87% | 8.34M | 3.09M | 8.34M | 3.09M | IN | — | 2021-05-24 | ↗ |
| 4 | Thomas C. Mollick | 9.81M | 1.60% | 9.81M | — | 9.81M | — | IN | — | 2021-06-08 | ↗ |
| 5 | Jack Chitayat | 4.53M | 0.74% | 2.07M | 2.46M | 2.07M | 2.46M | IN | — | 2021-06-08 | ↗ |
| 6 | William M. Rawson | 2.69M | 0.44% | 2.69M | — | 2.69M | — | IN | — | 2021-06-08 | ↗ |
| 7 | Thomas J. Errico M.D. | 2.51M | 0.41% | 2.51M | — | 2.51M | — | IN | — | 2021-06-08 | ↗ |
| 8 | Glenn Eisenberg | 1.99M | 0.33% | 1.99M | — | 1.99M | — | IN | — | 2021-06-08 | ↗ |
| 9 | Yaron Okun | 1.80M | 0.29% | 1.80M | — | 1.80M | — | IN | — | 2021-06-08 | ↗ |
| 10 | Allen Gabriel | 1.66M | 0.27% | 1.66M | — | 1.66M | — | IN | — | 2021-06-08 | ↗ |
| 11 | Anthony Caracciolo | 1.37M | 0.22% | 1.37M | — | 1.37M | — | IN | — | 2021-06-08 | ↗ |
| 12 | Paul A. Rosenbaum | 1.30M | 0.21% | 1.30M | — | 1.30M | — | IN | — | 2021-06-08 | ↗ |
| 13 | Paul Hydok | 1.23M | 0.20% | 1.23M | — | 1.23M | — | IN | — | 2021-06-08 | ↗ |
| 14 | Jeffrey Paul Beaty | 888.9K | 0.15% | 888.9K | — | 888.9K | — | IN | — | 2021-06-08 | ↗ |
| 15 | Francesco Tosco | 638.0K | 0.10% | 638.0K | — | 638.0K | 11.00 | IN | — | 2021-06-08 | ↗ |
| 16 | Brendan Thorson | 635.1K | 0.10% | 195.1K | 440.0K | 195.1K | 11.00 | IN | — | 2021-06-08 | ↗ |
| 17 | Joe Rector | 618.8K | 0.10% | 618.8K | — | 618.8K | 11.00 | IN | — | 2021-06-08 | ↗ |
| 18 | Jeffrey D. Weiner | 574.7K | 0.09% | 574.7K | — | 574.7K | — | IN | — | 2021-06-08 | ↗ |
| 19 | Steve Dalal | 548.1K | 0.09% | 548.1K | — | 548.1K | — | IN | — | 2021-06-08 | ↗ |
| 20 | Veronica Marano | 503.1K | 0.08% | — | 503.1K | — | 503.1K | IN | — | 2021-06-08 | ↗ |
| 21 | Jonathan Hartley | 450.0K | 0.07% | 450.0K | — | 450.0K | 11.00 | IN | — | 2021-06-08 | ↗ |
| 22 | Judson Longaker | 445.0K | 0.07% | 445.0K | — | 445.0K | — | IN | — | 2021-06-08 | ↗ |
| 23 | Charles M. Johnson Jr. | 425.2K | 0.07% | 425.2K | — | 425.2K | 11.00 | IN | — | 2021-06-08 | ↗ |
| 24 | Peter Christopher Caputo | 401.6K | 0.07% | 371.6K | 30.0K | 371.6K | 30.0K | IN | — | 2021-06-08 | ↗ |
| 25 | Antonio Parisi | 288.5K | 0.05% | — | 288.5K | — | 288.5K | IN | — | 2021-06-08 | ↗ |
| 26 | Arlyn J. Bossenbrook | 226.4K | 0.04% | 226.4K | — | 226.4K | — | IN | — | 2021-06-08 | ↗ |
| 27 | Frederick J. Axelberd | 121.5K | 0.02% | 121.5K | — | 121.5K | — | IN | — | 2021-06-08 | ↗ |
| 28 | Arthur L. Wilmes | 90.0K | 0.01% | — | 90.0K | — | 90.0K | IN | — | 2021-06-08 | ↗ |
| 29 | SCHEDULE 13D/A | 12.00 | 14.00% | 1.30M | — | 1.30M | — | IN | — | 2021-09-17 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
4
-5 vs prev Q
New positions
0
Closed positions
5
Increased
0
Reduced
0
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | NBC SECURITIES, INC. | 160.0K +— (+0.0%) | 43.8K -960.0 (-2.1%) | 0.01% 0.000 pp | 0.00% 0.000 pp | USD0.26 +3.8% | 3 qtrs — |
| 2 | DIVERSIFIED TRUST CO | 45.8K +— (+0.0%) | 12.5K -275.0 (-2.1%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD3.27 -91.7% | 40 qtrs — |
| 3 | HORIZON FINANCIAL SERVICES, LLC | 18.2K +— (+0.0%) | 5.0K -109.0 (-2.1%) | 0.00% +0.000 pp | 0.00% 0.000 pp | USD0.16 +68.8% | 9 qtrs — |
| 4 | NORTHSTAR ASSET MANAGEMENT LLC | 10.0K +— (+0.0%) | 2.7K -60.0 (-2.1%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD0.23 +17.4% | 5 qtrs — |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
This company is not held by any ETF in our universe.
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
1.71
Bullish
Ratio by volume
3.00
Bullish
Buys
12
Sells
7
Shares acquired
9.88M
Shares disposed
1.98M
Cash buys
—
Cash sales
—
Net activity
+7,900,000
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-20 | Urbach Tanya Durkee | Director | A-Award | A | Non-qualified stock option (right to buy) | 574,385 | 0.28 | 160.8K | 574,385 | D | ↗ |
| 2026-03-20 | SIMES STEPHEN M | Director | A-Award | A | Non-qualified stock option (right to buy) | 574,385 | 0.28 | 160.8K | 574,385 | D | ↗ |
| 2026-03-20 | Ndhlovu Lishomwa C | Director | A-Award | A | Non-qualified stock option (right to buy) | 574,385 | 0.28 | 160.8K | 574,385 | D | ↗ |
| 2026-03-20 | Lalezari Jacob P | Officer | A-Award | A | Non-qualified stock option (right to buy) | 4,874,691 | 0.28 | 1.36M | 4,874,691 | D | ↗ |
| 2026-03-20 | Hoffman Robert E. | Officer | A-Award | A | Non-qualified stock option (right to buy) | 4,874,691 | 0.28 | 1.36M | 4,874,691 | D | ↗ |
| 2026-03-20 | Dunlap Ryan | Director | A-Award | A | Non-qualified stock option (right to buy) | 574,385 | 0.28 | 160.8K | 574,385 | D | ↗ |
| 2026-03-20 | Brunke Karen J | Director | A-Award | A | Non-qualified stock option (right to buy) | 574,385 | 0.28 | 160.8K | 574,385 | D | ↗ |
| 2026-03-20 | Blok Tyler | Officer | A-Award | A | Non-qualified stock option (right to buy) | 3,249,794 | 0.28 | 909.9K | 3,249,794 | D | ↗ |
| 2025-05-15 | Hoffman Robert E. | Officer | A-Award | A | Non-qualified stock option (right to buy) | 1,000,000 | 0.41 | 410.0K | 1,000,000 | D | ↗ |
| 2024-10-28 | Urbach Tanya Durkee | Director | A-Award | A | Non-qualified stock option (right to buy) | 800,000 | 0.13 | 104.0K | 800,000 | D | ↗ |
| 2024-10-28 | SIMES STEPHEN M | Director | A-Award | A | Non-qualified stock option (right to buy) | 800,000 | 0.13 | 104.0K | 800,000 | D | ↗ |
| 2024-10-28 | Ndhlovu Lishomwa C | Director | A-Award | A | Non-qualified stock option (right to buy) | 800,000 | 0.13 | 104.0K | 800,000 | D | ↗ |
| 2024-10-28 | Lalezari Jacob P | Officer | A-Award | A | Non-qualified stock option (right to buy) | 3,000,000 | 0.13 | 390.0K | 3,000,000 | D | ↗ |
| 2024-10-28 | Dunlap Ryan | Director | A-Award | A | Non-qualified stock option (right to buy) | 800,000 | 0.13 | 104.0K | 800,000 | D | ↗ |
| 2024-10-28 | Brunke Karen J | Director | A-Award | A | Non-qualified stock option (right to buy) | 800,000 | 0.13 | 104.0K | 800,000 | D | ↗ |
| 2024-10-28 | Blok Tyler | Officer | A-Award | A | Non-qualified stock option (right to buy) | 1,250,000 | 0.13 | 162.5K | 1,250,000 | D | ↗ |
| 2024-03-07 | Lalezari Jacob P | Officer | A-Award | A | Non-qualified stock option (right to buy) | 3,000,000 | 0.21 | 630.0K | 3,000,000 | — | ↗ |
| 2024-02-01 | COHEN MITCHELL | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-01-03 | Urbach Tanya Durkee | Director | A-Award | A | Non-qualified stock option (right to buy) | 800,000 | 0.21 | 168.0K | 800,000 | — | ↗ |
| 2024-01-03 | SIMES STEPHEN M | Director | A-Award | A | Non-qualified stock option (right to buy) | 800,000 | 0.21 | 168.0K | 800,000 | — | ↗ |
| 2024-01-03 | Ndhlovu Lishomwa C | Director | A-Award | A | Non-qualified stock option (right to buy) | 800,000 | 0.21 | 168.0K | 800,000 | — | ↗ |
| 2024-01-03 | Migliarese Antonio | Officer | D-Return | D | Non-qualified stock option (right to buy) | 630,222 | 0.58 | 365.5K | 0 | — | ↗ |
| 2024-01-03 | Dunlap Ryan | Director | A-Award | A | Non-qualified stock option (right to buy) | 800,000 | 0.21 | 168.0K | 800,000 | — | ↗ |
| 2024-01-03 | Brunke Karen J | Director | A-Award | A | Non-qualified stock option (right to buy) | 800,000 | 0.21 | 168.0K | 800,000 | — | ↗ |
| 2024-01-03 | Blok Tyler | Officer | D-Return | D | Non-qualified stock option (right to buy) | 100,000 | 0.67 | 67.0K | 0 | — | ↗ |
| 2023-11-17 | Lalezari Jacob P | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-08-15 | Blok Tyler | Officer | — | D | Non-qualified stock option (right to buy) | 150,000 | 0.35 | 52.5K | 0 | — | ↗ |
| 2023-02-13 | Arman Arvin Cyrus | Officer | A-Award | A | Warrants (right to buy) | 434,782 | 0.50 | 217.4K | 434,782 | — | ↗ |
| 2022-11-30 | Migliarese Antonio | Officer | A-Award | A | Common Stock | 12,008 | 0.00 | — | 183,207 | — | ↗ |
| 2022-11-30 | Kelly Scott A. | Officer | A-Award | A | Common Stock | 16,927 | 0.00 | — | 2,184,037 | — | ↗ |
| 2022-11-28 | Migliarese Antonio | Officer | A-Award | A | Non-qualified stock option (right to buy) | 4,585,536 | 0.00 | — | 4,585,536 | — | ↗ |
| 2022-11-28 | Kelly Scott A. | Officer | A-Award | A | Non-qualified stock option (right to buy) | 2,315,439 | 0.00 | — | 2,315,439 | — | ↗ |
| 2022-11-15 | Ray Nitya G. | Officer | A-Award | A | Common Stock | 13,671 | 0.00 | — | 500,090 | — | ↗ |
| 2022-11-15 | Migliarese Antonio | Officer | A-Award | A | Common Stock | 10,807 | 0.00 | — | 171,199 | — | ↗ |
| 2022-11-15 | Kelly Scott A. | Officer | A-Award | A | Common Stock | 15,234 | 0.00 | — | 2,167,110 | — | ↗ |
| 2022-10-31 | Ray Nitya G. | Officer | A-Award | A | Common Stock | 16,084 | 0.00 | — | 486,419 | — | ↗ |
| 2022-10-31 | Migliarese Antonio | Officer | A-Award | A | Common Stock | 12,714 | 0.00 | — | 160,392 | — | ↗ |
| 2022-10-31 | Kelly Scott A. | Officer | A-Award | A | Common Stock | 17,922 | 0.00 | — | 2,151,876 | — | ↗ |
| 2022-10-24 | SIMES STEPHEN M | Director | A-Award | A | Non-qualified stock option (right to buy) | 178,012 | 0.00 | — | 178,012 | — | ↗ |
| 2022-10-15 | Ray Nitya G. | Officer | A-Award | A | Common Stock | 12,428 | 0.00 | — | 470,335 | — | ↗ |
| 2022-10-15 | Migliarese Antonio | Officer | A-Award | A | Common Stock | 9,824 | 0.00 | — | 147,678 | — | ↗ |
| 2022-10-15 | Kelly Scott A. | Officer | A-Award | A | Common Stock | 13,849 | 0.00 | — | 2,133,954 | — | ↗ |
| 2022-10-13 | SIMES STEPHEN M | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-09-30 | Ray Nitya G. | Officer | A-Award | A | Common Stock | 13,020 | 0.00 | — | 457,907 | — | ↗ |
| 2022-09-30 | Migliarese Antonio | Officer | A-Award | A | Common Stock | 10,292 | 0.00 | — | 137,854 | — | ↗ |
| 2022-09-30 | Kelly Scott A. | Officer | A-Award | A | Common Stock | 18,793 | 0.00 | — | 2,120,105 | — | ↗ |
| 2022-09-20 | Migliarese Antonio | Officer | A-Award | A | Non-qualified stock option (right to buy) | 630,222 | 0.58 | 365.5K | 630,222 | — | ↗ |
| 2022-09-20 | Arman Arvin Cyrus | Officer | A-Award | A | Non-qualified stock option (right to buy) | 1,575,557 | 0.58 | 913.8K | 1,575,557 | — | ↗ |
| 2022-09-15 | Ray Nitya G. | Officer | A-Award | A | Common Stock | 8,965 | 0.00 | — | 444,887 | — | ↗ |
| 2022-09-15 | Migliarese Antonio | Officer | A-Award | A | Common Stock | 7,086 | 0.00 | — | 127,562 | — | ↗ |
| 2022-09-15 | Kelly Scott A. | Director / Officer | A-Award | A | Common Stock | 9,457 | 0.00 | — | 2,101,312 | — | ↗ |
| 2022-09-06 | Urbach Tanya Durkee | Director | A-Award | A | Non-qualified stock option (right to buy) | 112,500 | 0.50 | 56.3K | 112,500 | — | ↗ |
| 2022-09-06 | Ndhlovu Lishomwa C | Director | A-Award | A | Non-qualified stock option (right to buy) | 50,000 | 0.50 | 25.0K | 50,000 | — | ↗ |
| 2022-09-06 | Dunlap Ryan | Director | A-Award | A | Non-qualified stock option (right to buy) | 185,333 | 0.50 | 92.7K | 185,333 | — | ↗ |
| 2022-09-06 | Brunke Karen J | Director | A-Award | A | Non-qualified stock option (right to buy) | 37,500 | 0.50 | 18.8K | 37,500 | — | ↗ |
| 2022-08-31 | Ray Nitya G. | Officer | A-Award | A | Common Stock | 10,516 | 0.00 | — | 435,922 | — | ↗ |
| 2022-08-31 | Migliarese Antonio | Officer | A-Award | A | Common Stock | 8,313 | 0.00 | — | 120,476 | — | ↗ |
| 2022-08-31 | Kelly Scott A. | Officer | A-Award | A | Common Stock | 11,094 | 0.00 | — | 2,091,855 | — | ↗ |
| 2022-08-25 | Dunlap Ryan | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-08-15 | Ray Nitya G. | Officer | A-Award | A | Common Stock | 6,588 | 0.00 | — | 425,406 | — | ↗ |
| 2022-08-15 | Migliarese Antonio | Officer | A-Award | A | Common Stock | 5,208 | 0.00 | — | 112,163 | — | ↗ |
| 2022-08-15 | Kelly Scott A. | Officer | A-Award | A | Common Stock | 6,950 | 0.00 | — | 2,080,761 | — | ↗ |
| 2022-07-31 | Ray Nitya G. | Officer | A-Award | A | Common Stock | 7,102 | 0.00 | — | 418,818 | — | ↗ |
| 2022-07-31 | Migliarese Antonio | Officer | A-Award | A | Common Stock | 5,614 | 0.00 | — | 106,955 | — | ↗ |
| 2022-07-31 | Kelly Scott A. | Officer | A-Award | A | Common Stock | 7,492 | 0.00 | — | 2,073,811 | — | ↗ |
| 2022-07-15 | Ray Nitya G. | Officer | A-Award | A | Common Stock | 12,428 | 0.00 | — | 411,716 | — | ↗ |
| 2022-07-15 | Migliarese Antonio | Officer | A-Award | A | Common Stock | 9,824 | 0.00 | — | 101,341 | — | ↗ |
| 2022-07-15 | Kelly Scott A. | Officer | A-Award | A | Common Stock | 13,112 | 0.00 | — | 2,066,319 | — | ↗ |
| 2022-07-09 | Arman Arvin Cyrus | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-06-30 | Ray Nitya G. | Officer | A-Award | A | Common Stock | 13,020 | 0.00 | — | 399,288 | — | ↗ |
| 2022-06-30 | Migliarese Antonio | Officer | A-Award | A | Common Stock | 10,292 | 0.00 | — | 91,517 | — | ↗ |
| 2022-06-30 | Kelly Scott A. | Officer | A-Award | A | Common Stock | 13,736 | 0.00 | — | 2,053,207 | — | ↗ |
| 2022-06-15 | Ray Nitya G. | Officer | A-Award | A | Common Stock | 13,671 | 0.00 | — | 386,268 | — | ↗ |
| 2022-06-15 | Migliarese Antonio | Officer | A-Award | A | Common Stock | 10,807 | 0.00 | — | 81,225 | — | ↗ |
| 2022-06-15 | Kelly Scott A. | Officer | A-Award | A | Common Stock | 14,423 | 0.00 | — | 2,039,471 | — | ↗ |
| 2022-05-15 | Ray Nitya G. | Officer | A-Award | A | Common Stock | 16,084 | 0.00 | — | 355,508 | — | ↗ |
| 2022-04-30 | Ray Nitya G. | Officer | A-Award | A | Common Stock | 17,089 | 0.00 | — | 339,424 | — | ↗ |
| 2022-04-15 | Ray Nitya G. | Officer | A-Award | A | Common Stock | 20,254 | 0.00 | — | 322,335 | — | ↗ |
| 2022-03-31 | Recknor Chris P | Officer | A-Award | A | Common Stock | 17,746 | 0.00 | — | 716,746 | — | ↗ |
| 2022-03-31 | Ray Nitya G. | Officer | A-Award | A | Common Stock | 14,780 | 0.00 | — | 302,081 | — | ↗ |
| 2022-03-31 | Migliarese Antonio | Officer | A-Award | A | Common Stock | 13,509 | 0.00 | — | 44,225 | — | ↗ |
| 2022-03-31 | Kelly Scott A. | Officer | A-Award | A | Common Stock | 18,029 | 0.00 | — | 2,025,048 | — | ↗ |
| 2022-03-30 | Brunke Karen J | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-02-17 | Migliarese Antonio | Officer | — | D | Non-qualified Stock Option (right to buy) | 50,000 | 5.54 | 277.0K | 0 | — | ↗ |
| 2021-11-24 | Urbach Tanya Durkee | Director | — | D | Common Stock | 0 | 0.00 | — | 162,113 | — | ↗ |
| 2021-11-24 | TIMMINS ALAN P | Director | D-Return | D | Non-qualified Stock Option | 225,000 | 6.15 | 1.38M | 0 | — | ↗ |
| 2021-11-24 | Seethamraju Harish | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-11-24 | Patel Samir Rashmikant | Director | D-Return | D | Non-qualified Stock Option | 225,000 | 1.39 | 312.8K | 0 | — | ↗ |
| 2021-11-24 | Ndhlovu Lishomwa C | Director | — | D | Stock Option (right to buy) | 50,000 | 3.36 | 168.0K | 0 | — | ↗ |
| 2021-11-24 | Gardiner Gordon A | Director | A-Award | A | Non-qualified Stock Option | 937,500 | 1.39 | 1.30M | 93,750 | — | ↗ |
| 2021-10-18 | TIMMINS ALAN P | Director | A-Award | A | Non-qualified Stock Option | 225,000 | 1.39 | 312.8K | 225,000 | — | ↗ |
| 2021-10-18 | Pourhassan Nader | Director / Officer | A-Award | A | Non-qualified Stock Option | 4,275,000 | 1.39 | 5.94M | 4,275,000 | — | ↗ |
| 2021-10-18 | Patel Samir Rashmikant | Director | A-Award | A | Non-qualified Stock Option | 225,000 | 1.39 | 312.8K | 225,000 | — | ↗ |
| 2021-10-18 | Naydenov Jordan G | Director | A-Award | A | Non-qualified Stock Option | 225,000 | 1.39 | 312.8K | 225,000 | — | ↗ |
| 2021-10-18 | Kelly Scott A. | Director / Officer | A-Award | A | Non-qualified Stock Option | 1,750,000 | 1.39 | 2.43M | 1,750,000 | — | ↗ |
| 2021-10-18 | Gardiner Gordon A | Director | A-Award | A | Non-qualified Stock Option | 225,000 | 1.39 | 312.8K | 225,000 | — | ↗ |
| 2021-09-23 | Naydenov Jordan G | Director | A-Award | A | Warrant (Right to Buy) | 133,332 | 0.75 | 100.0K | 133,332 | — | ↗ |
| 2021-08-06 | Recknor Chris P | Officer | A-Award | A | Common stock | 19,384 | 0.00 | — | 686,050 | — | ↗ |
| 2021-08-06 | Ray Nitya G. | Officer | A-Award | A | Common stock | 52,500 | 0.00 | — | 287,301 | — | ↗ |
| 2021-08-06 | Pourhassan Nader | Director / Officer | A-Award | A | Common stock | 200,000 | 0.00 | — | 1,850,688 | — | ↗ |
| 2021-08-06 | Migliarese Antonio | Officer | A-Award | A | Non-qualified stock option (right to buy) | 1,000,000 | 1.32 | 1.32M | 1,000,000 | — | ↗ |
| 2021-08-06 | Kelly Scott A. | Director / Officer | A-Award | A | Common stock | 40,661 | 0.00 | — | 1,781,713 | — | ↗ |
| 2021-07-22 | Migliarese Antonio | Officer | — | D | Non-qualified Stock Option (right to buy) | 100,000 | 5.57 | 557.0K | 0 | — | ↗ |
| 2021-07-01 | Gardiner Gordon A | Director | — | D | Common Stock | 0 | 0.00 | — | 1,000 | — | ↗ |
| 2021-04-19 | Naydenov Jordan G | Director | X-InTheMoney | D | Warrant (right to buy) | 250,000 | 1.35 | 337.5K | 0 | — | ↗ |
| 2021-03-11 | Recknor Chris P | Officer | — | D | Common Stock | 0 | 0.00 | — | 666,666 | — | ↗ |
| 2021-02-21 | Migliarese Antonio | Officer | — | D | Non-qualified Stock Option (right to buy) | 50,000 | 1.10 | 55.0K | 0 | — | ↗ |
| 2021-02-05 | Kelly Scott A. | Director / Officer | M-Exempt | A | Common Stock | 166,000 | 0.75 | 124.5K | 782,408 | — | ↗ |
| 2021-01-16 | Migliarese Antonio | Officer | — | D | Non-qualified Stock Option (right to buy) | 50,000 | 1.03 | 51.5K | 0 | — | ↗ |
| 2020-12-22 | Mulholland Michael D. | Officer | S-Sale | D | Common Stock | 453,997 | 6.61 | 3.00M | 296,181 | — | ↗ |
| 2020-12-21 | Mulholland Michael D. | Officer | M-Exempt | A | Non-qualified Stock Option (right to buy) | 201,598 | 0.57 | 114.9K | 0 | D | ↗ |
| 2020-12-18 | Mulholland Michael D. | Officer | M-Exempt | A | Non-qualified Stock Option (right to buy) | 155,500 | 0.39 | 60.6K | 0 | D | ↗ |
| 2020-12-17 | Mulholland Michael D. | Officer | S-Sale | D | Common Stock | 32,000 | 4.55 | 145.7K | 284,081 | D | ↗ |
| 2020-11-02 | Naydenov Jordan G | Director | P-Purchase | A | Common Stock | 193,500 | 2.57 | 497.3K | 6,451,323 | — | ↗ |
| 2020-10-23 | Naydenov Jordan G | Director | P-Purchase | A | Common Stock | 120,000 | 2.49 | 298.3K | 6,257,823 | — | ↗ |
| 2020-10-23 | Colachis Arian | Officer | P-Purchase | A | Common Stock | 10,000 | 2.50 | 25.0K | 80,000 | — | ↗ |
| 2020-10-16 | Rahman Mahboob U | Officer | A-Award | A | Common Stock | 200,000 | 0.00 | — | 200,000 | — | ↗ |
| 2020-09-30 | Ray Nitya G. | Officer | A-Award | A | Non-qualified Stock Option | 500,000 | 3.12 | 1.56M | 500,000 | — | ↗ |
| 2020-09-30 | Pourhassan Nader | Director / Officer | A-Award | A | Non-qualified Stock Option | 2,000,000 | 3.12 | 6.24M | 2,000,000 | — | ↗ |
| 2020-09-30 | Mulholland Michael D. | Officer | A-Award | A | Common Stock | 100,000 | 0.00 | — | 284,081 | — | ↗ |
| 2020-09-30 | Kelly Scott A. | Director / Officer | A-Award | A | Common Stock | 250,000 | 0.00 | — | 1,741,052 | — | ↗ |
| 2020-09-30 | Colachis Arian | Officer | A-Award | A | Non-qualified Stock Option | 150,000 | 3.12 | 468.0K | 150,000 | — | ↗ |
| 2020-08-28 | Kelly Scott A. | Director / Officer | G-Gift | A | Common Stock | 74,800 | 0.00 | — | 97,980 | — | ↗ |
| 2020-07-31 | Pourhassan Nader | Director / Officer | A-Award | A | Common Stock | 323,157 | 0.00 | — | 1,231,500 | — | ↗ |
| 2020-06-25 | Welch David F | Director | A-Award | A | Non-qualified Stock Option | 225,000 | 6.15 | 1.38M | 225,000 | — | ↗ |
| 2020-06-25 | TIMMINS ALAN P | Director | A-Award | A | Non-qualified Stock Option | 225,000 | 6.15 | 1.38M | 225,000 | — | ↗ |
| 2020-06-25 | Patel Samir Rashmikant | Director | A-Award | A | Non-qualified Stock Option | 225,000 | 6.15 | 1.38M | 225,000 | — | ↗ |
| 2020-06-25 | Naydenov Jordan G | Director | A-Award | A | Non-qualified Stock Option | 225,000 | 6.15 | 1.38M | 225,000 | — | ↗ |
| 2020-06-10 | Recknor Chris P | Officer | — | D | Non-qualified Stock Option (right to buy) | 50,000 | 6.15 | 307.5K | 0 | — | ↗ |
| 2020-05-31 | Patel Samir Rashmikant | Director | — | D | Stock Option | 12,329 | 2.25 | 27.7K | 0 | — | ↗ |
| 2020-05-31 | Kelly Scott A. | Director / Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2020-05-05 | Kelly Scott A. | Director / Officer | M-Exempt | A | Nonqualified Option - right to buy | 8,334 | 0.52 | 4.3K | 25,000 | D | ↗ |
| 2020-05-04 | Pourhassan Nader | Director / Officer | M-Exempt | A | Common Stock | 30,933 | 0.39 | 12.1K | 2,109,995 | — | ↗ |
| 2020-05-04 | Kelly Scott A. | Director / Officer | M-Exempt | A | Nonqualified Stock Option-right to buy | 8,334 | 0.52 | 4.3K | 25,000 | D | ↗ |
| 2020-05-01 | Pourhassan Nader | Director / Officer | S-Sale | D | Common Stock | 1,399,685 | 3.26 | 4.57M | 2,079,062 | — | ↗ |
| 2020-05-01 | Kelly Scott A. | Director / Officer | M-Exempt | A | Nonqualified Stock Option-right to buy | 93,750 | 0.39 | 36.6K | 0 | D | ↗ |
| 2020-04-30 | Pourhassan Nader | Director / Officer | M-Exempt | A | Employee Stock Option | 600,000 | 1.09 | 654.0K | 0 | — | ↗ |
| 2020-04-17 | Patel Samir Rashmikant | Director | — | I | Common Stock | 0 | 0.00 | — | 7,218,874 | — | ↗ |
| 2020-04-01 | Welch David F | Director | M-Exempt | A | Common Stock | 2,259,102 | 0.50 | 1.13M | 9,513,417 | — | ↗ |
| 2020-03-16 | Colachis Arian | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2020-02-21 | Welch David F | Director | M-Exempt | D | Warrant (Right to BuyO | 1,819,672 | 0.18 | 327.5K | 0 | — | ↗ |
| 2020-02-21 | Eastwood Craig S. | Officer | A-Award | A | Stock Option (right to buy) | 150,000 | 1.10 | 165.0K | 150,000 | — | ↗ |
| 2020-01-31 | Welch David F | Director | P-Purchase | A | Series D Convertible Preferred Stock | 1,000 | 0.80 | 800.00 | 1,000 | — | ↗ |
| 2020-01-18 | TIMMINS ALAN P | Director | A-Award | A | Stock Option (right to buy) | 36,986 | 1.05 | 38.8K | 36,986 | — | ↗ |
| 2020-01-06 | Fleming Maura | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2019-12-24 | Pourhassan Nader | Director / Officer | A-Award | A | Common Stock | 225,983 | 0.00 | — | 387,472 | — | ↗ |
| 2019-12-24 | Mulholland Michael D. | Officer | F-InKind | D | Common Stock | 56,942 | 0.64 | 36.4K | 184,081 | — | ↗ |
| 2019-12-23 | Welch David F | Director | A-Award | A | Common Stock | 1,639,344 | 0.31 | 500.0K | 5,252,676 | — | ↗ |
| 2019-12-19 | Welch David F | Director | A-Award | A | Stock Option (right to buy) | 750,000 | 0.63 | 472.5K | 750,000 | — | ↗ |
| 2019-12-19 | Ray Nitya G. | Officer | A-Award | A | Stock Option (right to buy) | 600,000 | 0.63 | 378.0K | 600,000 | — | ↗ |
| 2019-12-19 | Pourhassan Nader | Director / Officer | A-Award | A | Warrant (right to buy) | 2,000,000 | 0.63 | 1.26M | 2,000,000 | — | ↗ |
| 2019-12-19 | Naydenov Jordan G | Director | A-Award | A | Stock Option (right to buy) | 750,000 | 0.63 | 472.5K | 750,000 | — | ↗ |
| 2019-12-19 | Mulholland Michael D. | Officer | A-Award | A | Stock Option (right to buy) | 700,000 | 0.63 | 441.0K | 700,000 | — | ↗ |
| 2019-12-19 | Klump Michael A | Director | A-Award | A | Stock Option (right to buy) | 750,000 | 0.63 | 472.5K | 750,000 | — | ↗ |
| 2019-12-19 | Kelly Scott A. | Director | A-Award | A | Stock Option (right to buy) | 1,250,000 | 0.63 | 787.5K | 1,250,000 | — | ↗ |
| 2019-12-13 | Naydenov Jordan G | Director | A-Award | A | Common Stock | 833,333 | 0.30 | 250.0K | 6,137,823 | — | ↗ |
| 2019-11-13 | Eastwood Craig S. | Officer | A-Award | A | Stock Option (right to buy) | 250,000 | 0.30 | 75.0K | 250,000 | — | ↗ |
| 2019-10-08 | Klump Michael A | Director | A-Award | A | Convertible Promissory Note | 537,397 | 0.50 | 268.7K | 0 | — | ↗ |
| 2019-10-07 | Welch David F | Director | A-Award | D | Stock Options (right to buy) | 187,500 | 0.39 | 73.1K | 187,500 | — | ↗ |
| 2019-10-07 | Ray Nitya G. | Officer | A-Award | A | Stock Options (right to buy) | 187,500 | 0.39 | 73.1K | 187,500 | — | ↗ |
| 2019-10-07 | Pourhassan Nader | Director / Officer | A-Award | A | Stock Options (right to buy) | 375,000 | 0.39 | 146.3K | 375,000 | — | ↗ |
| 2019-10-07 | Mulholland Michael D. | Officer | A-Award | A | Stock Options (right to buy) | 187,500 | 0.39 | 73.1K | 187,500 | — | ↗ |
| 2019-10-07 | Kelly Scott A. | Director | A-Award | A | Stock Options (right to buy) | 187,500 | 0.39 | 73.1K | 187,500 | — | ↗ |
| 2019-09-30 | Welch David F | Director | D-Return | D | Convertible Promissory Note | 1,000,000 | 0.50 | 500.0K | 0 | — | ↗ |
| 2019-09-12 | Welch David F | Director | A-Award | A | Stock Options (right to buy) | 250,000 | 0.39 | 96.3K | 250,000 | — | ↗ |
| 2019-09-12 | Kelly Scott A. | Director | A-Award | A | Stock Options (right to buy) | 750,000 | 0.39 | 288.8K | 750,000 | — | ↗ |
| 2019-07-31 | Welch David F | Director | A-Award | A | Common Stock | 500,000 | 0.00 | 500.00 | 4,502,202 | — | ↗ |
| 2019-06-18 | Welch David F | Director | A-Award | A | Stock Options (right to buy) | 100,000 | 0.52 | 52.0K | 100,000 | — | ↗ |
| 2019-06-18 | Pourhassan Nader | Director / Officer | A-Award | A | Stock Options (right to buy) | 50,000 | 0.90 | 45.0K | 50,000 | — | ↗ |
| 2019-06-18 | Naydenov Jordan G | Director | A-Award | A | Stock Options (right to buy) | 100,000 | 0.52 | 52.0K | 100,000 | — | ↗ |
| 2019-06-18 | Klump Michael A | Director | A-Award | A | Stock Options (right to buy) | 100,000 | 0.52 | 52.0K | 100,000 | — | ↗ |
| 2019-06-18 | Kelly Scott A. | Director | A-Award | A | Stock Options (right to buy) | 100,000 | 0.52 | 52.0K | 100,000 | — | ↗ |
| 2019-06-18 | Gould Gregory A | Director | A-Award | A | Stock Options (right to buy) | 100,000 | 0.52 | 52.0K | 100,000 | — | ↗ |
| 2019-06-18 | DOCKERY CARL | Director | A-Award | A | Stock Options (right to buy) | 100,000 | 0.52 | 52.0K | 100,000 | — | ↗ |
| 2019-06-12 | Kelly Scott A. | Director | M-Exempt | D | Warrant (Right to Buy) | 50,000 | 0.40 | 20.0K | 0 | — | ↗ |
| 2019-06-12 | DOCKERY CARL | Director | A-Award | A | Warrant (Right to Buy) | 66,667 | 0.40 | 26.7K | 66,667 | — | ↗ |
| 2019-05-08 | Welch David F | Director | A-Award | A | Warrant (Right to Buy) | 600,000 | 0.40 | 240.0K | 600,000 | — | ↗ |
| 2019-05-08 | Klump Michael A | Director | M-Exempt | D | Warrant (Right to Buy) | 500,000 | 0.30 | 150.0K | 0 | — | ↗ |
| 2019-05-08 | DOCKERY CARL | Director | A-Award | A | Warrant (Right to Buy) | 75,000 | 0.40 | 30.0K | 75,000 | — | ↗ |
| 2019-02-16 | Kelly Scott A. | Director | A-Award | A | Warrants (right to buy) | 500,000 | 0.51 | 255.0K | 500,000 | — | ↗ |
| 2019-01-10 | Welch David F | Director | — | I | Convertible Promissory Note | 2,000,000 | 0.50 | 1.00M | 0 | — | ↗ |
| 2019-01-10 | Caracciolo Anthony | Director | D-Return | D | Stock Options (right to buy) | 100,000 | 0.64 | 64.0K | 0 | — | ↗ |
| 2019-01-08 | Klump Michael A | Director | P-Purchase | A | Warrants | 500,000 | 0.30 | 150.0K | 500,000 | — | ↗ |
| 2018-12-22 | Ray Nitya G. | Officer | A-Award | A | Stock Options (right to buy) | 400,000 | 0.48 | 192.0K | 400,000 | — | ↗ |
| 2018-12-11 | Patel Samir Rashmikant | Director | — | I | Warrant | 150,000 | 0.75 | 112.5K | 0 | — | ↗ |
| 2018-11-16 | Pourhassan Nader | Director / Officer | A-Award | A | Stock Options (right to buy) | 350,000 | 0.49 | 171.5K | 350,000 | — | ↗ |
| 2018-11-16 | Pestell Richard MD | Director / Officer | A-Award | A | Stock Options (right to buy) | 350,000 | 0.55 | 192.9K | 350,000 | — | ↗ |
| 2018-11-16 | Naydenov Jordan G | Director | A-Award | A | Common Stock | 5,304,490 | 0.00 | — | 5,304,490 | — | ↗ |
| 2018-11-16 | Mulholland Michael D. | Officer | A-Award | A | Stock Options (right to buy) | 150,000 | 0.64 | 96.0K | 150,000 | — | ↗ |
| 2018-11-16 | Klump Michael A | Director | A-Award | A | Warrants (right to buy) | 66,667 | 1.00 | 66.7K | 66,667 | — | ↗ |
| 2018-11-16 | Kelly Scott A. | Director | A-Award | A | Warrants (right to buy) | 50,000 | 1.35 | 67.5K | 50,000 | — | ↗ |
| 2018-11-16 | Gould Gregory A | Director | A-Award | A | Stock Options (right to buy) | 75,000 | 0.57 | 42.8K | 75,000 | — | ↗ |
| 2018-11-16 | DOCKERY CARL | Director | A-Award | A | Stock Options (right to buy) | 75,000 | 0.57 | 42.8K | 75,000 | — | ↗ |
| 2018-11-16 | Caracciolo Anthony | Director | D-Return | D | Stock Options (right to buy) | 50,000 | 0.80 | 40.0K | 0 | — | ↗ |
| 2018-11-08 | Pourhassan Nader | Director / Officer | A-Award | A | Stock Options (right to buy) | 1,000,000 | 0.57 | 565.0K | 1,000,000 | — | ↗ |
| 2018-11-08 | Kelly Scott A. | Director | A-Award | A | Stock Options (right to buy) | 250,000 | 0.57 | 141.3K | 250,000 | — | ↗ |
| 2018-11-08 | DOCKERY CARL | Director | A-Award | A | Stock Options (right to buy) | 250,000 | 0.57 | 141.3K | 250,000 | — | ↗ |
| 2018-08-10 | Klump Michael A | Director | — | I | Common Stock | 0 | 0.00 | — | 7,034,520 | — | ↗ |
| 2018-07-12 | Montgomery Alan Bruce | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2018-07-12 | BURGER DENIS R | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
Executive team
Top executives
EBIT / Employee
955.7K
Shares Outstanding
1.37B
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Jacob P. Lalezari, M.D. Chief Executive Officer | 400.0K | 30.0K | 342.0K | — | — | 11.9K | 783.9K | 43.63% | ↗ |
| 2 | 2025 | Mitchell Cohen Interim Chief Financial Officer | 576.0K | — | — | — | — | — | 576.0K | 0.00% | ↗ |
| 3 | 2025 | Tyler Blok Chief Legal Officer | 365.0K | 15.0K | 142.5K | — | — | 10.0K | 532.5K | 26.76% | ↗ |
| 4 | 2025 | Robert E. Hoffman Chief Financial Officer | 20.0K | — | 368.5K | — | — | — | 388.5K | 94.85% | ↗ |
| 5 | 2024 | Jacob P. Lalezari, M.D. Chief Executive Officer | 152.2K | 70.0K | 459.6K | — | — | 3.5K | 685.4K | 67.06% | ↗ |
| 6 | 2024 | Jacob Lalezari, M.D. Chief Executive Officer | 152.2K | 70.0K | 459.6K | — | — | 3.5K | 685.4K | 67.06% | ↗ |
| 7 | 2024 | Tyler Blok Chief Legal Officer | 291.0K | — | 176.1K | — | 100.0K | 8.7K | 575.8K | 30.57% | ↗ |
| 8 | 2024 | Antonio Migliarese Chief Financial Officer | 384.7K | — | 90.6K | — | — | 8.0K | 483.2K | 18.74% | ↗ |
| 9 | 2024 | Cyrus Arman, Ph.D. President | 270.0K | — | 109.5K | — | — | 8.1K | 387.6K | 28.25% | ↗ |
| 10 | 2024 | Mitchell Cohen Interim Chief Financial Officer | 218.4K | — | — | — | — | — | 218.4K | 0.00% | ↗ |
| 11 | 2023 | Antonio Migliarese Chief Financial Officer | 428.4K | — | 1.32M | — | — | 10.1K | 1.76M | 75.05% | ↗ |
| 12 | 2023 | Cyrus Arman, Ph.D. President | 394.7K | — | 1.13M | — | — | 8.7K | 1.53M | 73.61% | ↗ |
| 13 | 2023 | Scott A. Kelly, M.D. Chief Medical Officer | 299.8K | — | 665.9K | — | — | 2.2K | 968.0K | 68.80% | ↗ |
| 14 | 2023 | Nitya G. Ray, Ph.D. Chief Technology Officer | 249.4K | — | — | — | — | 2.6K | 252.0K | 0.00% | ↗ |
| 15 | 2022 | Nader Z. Pourhassan, Ph.D. President and Chief Executive Officer | 431.2K | — | 4.59M | — | — | 1.01M | 6.03M | 76.09% | ↗ |
| 16 | 2022 | Scott A. Kelly, M.D. Chief Medical Officer | 585.0K | — | 1.88M | — | — | 16.6K | 2.48M | 75.73% | ↗ |
| 17 | 2022 | Chris P. Recknor, M.D. Sr. Executive VP of Clinical Operations | 436.0K | — | 1.48M | — | — | 13.1K | 1.93M | 76.68% | ↗ |
| 18 | 2022 | Antonio Migliarese Chief Financial Officer | 433.2K | — | 1.30M | — | — | 12.3K | 1.75M | 74.51% | ↗ |
| 19 | 2022 | Nitya G. Ray, Ph.D. Chief Technology Officer | 497.7K | — | 528.3K | — | — | 14.4K | 1.04M | 50.76% | ↗ |
| 20 | 2021 | Nader Z. Pourhassan, Ph.D. President and Chief Executive Officer | 1.00M | 800.0K | 7.99M | — | 200.0K | 57.4K | 10.05M | 79.52% | ↗ |
| 21 | 2021 | Scott A. Kelly, M.D. Chief Medical Officer | 700.0K | 200.0K | 2.29M | — | 107.3K | 37.8K | 3.33M | 68.64% | ↗ |
| 22 | 2021 | Nitya G. Ray, Ph.D. Chief Technology Officer | 525.0K | 150.0K | 1.84M | — | 91.9K | 30.6K | 2.63M | 69.73% | ↗ |
| 23 | 2020 | Nader Z. Pourhassan, Ph.D. President and Chief Executive Officer | 865.7K | 617.5K | 8.44M | — | — | 45.9K | 9.97M | 84.66% | ↗ |
| 24 | 2020 | Craig S. Eastwood Former Chief Financial Officer | 192.7K | — | 180.0K | 159.1K | — | 249.2K | 781.0K | 43.42% | ↗ |
| 25 | 2020 | Nitya G. Ray, Ph.D. Chief Technology Officer | 400.0K | 150.0K | 212.5K | — | — | 13.0K | 775.5K | 27.40% | ↗ |
| 26 | 2020 | Michael D. Mulholland Chief Financial Officer | 427.2K | — | — | 239.3K | — | 18.3K | 684.7K | 34.94% | ↗ |
| 27 | 2019 | Nader Z. Pourhassan, President and Chief Executive Officer | 506.1K | 683.3K | 312.9K | — | — | 18.2K | 1.52M | 20.57% | ↗ |
| 28 | 2019 | Nader Z. Pourhassan, Ph.D. President and Chief Executive Officer | 506.1K | 683.3K | — | 312.9K | — | 18.2K | 1.52M | 20.58% | ↗ |
| 29 | 2019 | Anthony D. Caracciolo, Executive Chairman | 131.9K | — | — | — | — | 688.0K | 819.6K | 0.00% | ↗ |
| 30 | 2019 | Richard G. Pestell, Chief Medical Officer | 275.0K | 123.8K | 118.8K | — | — | 93.3K | 610.8K | 19.45% | ↗ |
| 31 | 2019 | Michael D. Mulholland, Chief Financial Officer | 363.0K | 138.7K | — | — | — | 13.1K | 515.6K | 0.00% | ↗ |
| 32 | 2019 | Michael D. Mulholland Chief Financial Officer | 363.0K | 138.7K | — | — | — | 13.1K | 514.7K | 0.00% | ↗ |
| 33 | 2019 | Nitya G. Ray, Ph.D. Chief Technology Officer | 167.0K | 183.5K | — | 116.8K | — | 5.3K | 472.6K | 24.71% | ↗ |
| 34 | 2019 | Craig S. Eastwood Former Chief Financial Officer | 28.7K | — | — | 27.2K | — | — | 55.9K | 48.68% | ↗ |
| 35 | 2018 | Nader Z. Pourhassan, President and Chief Executive Officer | 433.9K | 216.9K | 293.2K | — | — | 21.4K | 966.6K | 30.33% | ↗ |
| 36 | 2018 | Michael D. Mulholland, Chief Financial Officer | 347.6K | 147.7K | 200.2K | — | — | 13.8K | 709.5K | 28.22% | ↗ |
| 37 | 2018 | Anthony D. Caracciolo, Executive Chairman | 200.0K | — | 442.5K | — | — | 4.8K | 647.3K | 68.35% | ↗ |
| 38 | 2017 | Nader Z. Pourhassan, President and Chief Executive Officer | 421.3K | 252.8K | 456.7K | — | — | 12.6K | 1.14M | 39.94% | ↗ |
| 39 | 2017 | Michael D. Mulholland, Chief Financial Officer | 337.5K | 101.3K | 228.3K | — | — | 10.1K | 677.2K | 33.72% | ↗ |
| 40 | 2017 | Anthony D. Caracciolo Executive Chairman | 69.8K | — | — | 352.3K | — | — | 422.0K | 83.47% | ↗ |
| 41 | 2017 | Anthony D. Caracciolo, Executive Chairman | 69.8K | — | 352.3K | — | — | — | 422.0K | 83.47% | ↗ |
| 42 | 2016 | Nader Z. Pourhassan, President and Chief Executive Officer | 341.3K | 276.0K | 696.3K | — | — | 10.2K | 1.32M | 52.60% | ↗ |
| 43 | 2016 | Michael D. Mulholland, Chief Financial Officer | 262.5K | 152.8K | 414.9K | — | — | 7.9K | 838.1K | 49.51% | ↗ |
| 44 | 2015 | Nader Z. Pourhassan, President and Chief Executive Officer | 300.0K | 210.0K | — | 96.4K | — | 9.0K | 615.4K | 15.67% | ↗ |
| 45 | 2015 | Nader Z. Pourhassan, President and Chief Executive Officer | 300.0K | 210.0K | — | 96.4K | — | 9.0K | 615.4K | 15.67% | ↗ |
| 46 | 2015 | Michael D. Mulholland, Chief Financial Officer | 239.6K | 101.8K | — | 72.3K | — | 7.2K | 420.9K | 17.18% | ↗ |
| 47 | 2015 | Michael D. Mulholland, Chief Financial Officer | 239.6K | 101.8K | — | 72.3K | — | 7.2K | 420.9K | 17.18% | ↗ |
| 48 | 2014 | Nader Z. Pourhassan, President and Chief Executive Officer | 265.0K | 100.0K | — | 72.7K | — | 9.9K | 447.5K | 16.24% | ↗ |
| 49 | 2014 | Nader Z. Pourhassan, President and Chief Executive Officer | 265.0K | 100.0K | — | 72.7K | — | 9.9K | 447.5K | 16.24% | ↗ |
| 50 | 2014 | Michael D. Mulholland, Chief Financial Officer | 225.0K | 92.5K | — | 54.5K | — | 8.1K | 380.1K | 14.34% | ↗ |
| 51 | 2014 | Michael D. Mulholland, Chief Financial Officer | 225.0K | 92.5K | — | 54.5K | — | 8.1K | 380.1K | 14.34% | ↗ |
| 52 | 2013 | Nader Z. Pourhassan, President and Chief Executive Officer | 213.0K | 177.5K | — | 409.4K | — | 7.9K | 807.7K | 50.68% | ↗ |
| 53 | 2013 | Michael D. Mulholland, Chief Financial Officer | 82.2K | 87.5K | — | 241.3K | — | 1.3K | 412.3K | 58.52% | ↗ |
| 54 | 2013 | Michael D. Mulholland, Chief Financial Officer | 82.2K | 87.5K | — | 241.3K | — | 1.3K | 412.3K | 58.52% | ↗ |
| 55 | 2013 | Richard J. Trauger, former Chief Scientific Officer | 140.3K | 50.0K | — | 89.3K | — | 26.7K | 306.4K | 29.16% | ↗ |
| 56 | 2011 | Andrew T. Libby, Jr. Chief Financial Officer and Corporate Secretary | 12.0K | — | — | — | — | — | 12.0K | 0.00% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Robert E. Hoffman | Chief Financial Officer | 444.4K | male |
| Jacob Lalezari | Chief Executive Officer | 441.9K | — |
| Tyler Blok | Chief Legal Officer & Corporate Secretary | 390.0K | male |
| Cyrus Arman | Senior Vice President of Business Operations | 278.1K | male |
| Max Lataillade | Senior Vice President & Head of Clinical Development | — | — |
| Cristina De Leon | Investors | — | female |
| Bernie Cunningham | Vice President of Operations | — | — |
| Scott Hansen | Head of Research & Basic Science | — | — |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for CYDY
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
